Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Carcinoma, Renal Cell
  • Interferon-alpha
  • Kidney Neoplasms

abstract

  • PEG-IFN is a modified form of IFNalpha2a with distinct pharmacokinetic advantages and immunomodulatory and antitumor activity for patients with advanced RCC. A dose of 450 microg/wk by subcutaneous administration was determined as a suitable dose for further study. PEG-IFN is more convenient to administer than IFNalpha and has potential for increased efficacy, less toxicity, or both. The efficacy and toxicity of PEG-IFN will be further assessed in clinical trials and compared with IFNalpha.

publication date

  • March 2001

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 11230473

Additional Document Info

start page

  • 1312

end page

  • 9

volume

  • 19

number

  • 5